The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chronic Obstructive Pulmonary Diseases Drugs Market Research Report 2024
Synopsis
Chronic obstructive pulmonary disease (COPD) is a chronic bronchitis and/or emphysema characterized by airflow obstruction, which can further develop into a common chronic disease of cor pulmona and respiratory failure.It is related to the abnormal inflammatory reaction of harmful gases and harmful particles. The morbidity rate and fatality rate are very high, and the global morbidity rate over 40 years old is as high as 9% ~ 10%.
The global Chronic Obstructive Pulmonary Diseases Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Chronic Obstructive Pulmonary Diseases Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Obstructive Pulmonary Diseases Drugs.
Report Scope
The Chronic Obstructive Pulmonary Diseases Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Obstructive Pulmonary Diseases Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Obstructive Pulmonary Diseases Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Circassia Pharmaceuticals
AstraZeneca
GlaxoSmithKline
Mylan
Boehringer Ingelheim
Pfizer
Almirall
Abbott Laboratories
Novartis
Teva Pharmaceutical Industries
Segment by Type
Oral Medicine
Injection Medicine
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Obstructive Pulmonary Diseases Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Chronic obstructive pulmonary disease (COPD) is a chronic bronchitis and/or emphysema characterized by airflow obstruction, which can further develop into a common chronic disease of cor pulmona and respiratory failure.It is related to the abnormal inflammatory reaction of harmful gases and harmful particles. The morbidity rate and fatality rate are very high, and the global morbidity rate over 40 years old is as high as 9% ~ 10%.
The global Chronic Obstructive Pulmonary Diseases Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Chronic Obstructive Pulmonary Diseases Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Obstructive Pulmonary Diseases Drugs.
Report Scope
The Chronic Obstructive Pulmonary Diseases Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Obstructive Pulmonary Diseases Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Obstructive Pulmonary Diseases Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Circassia Pharmaceuticals
AstraZeneca
GlaxoSmithKline
Mylan
Boehringer Ingelheim
Pfizer
Almirall
Abbott Laboratories
Novartis
Teva Pharmaceutical Industries
Segment by Type
Oral Medicine
Injection Medicine
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Obstructive Pulmonary Diseases Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Obstructive Pulmonary Diseases Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral Medicine
1.2.3 Injection Medicine
1.3 Market by Application
1.3.1 Global Chronic Obstructive Pulmonary Diseases Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Obstructive Pulmonary Diseases Drugs Market Perspective (2019-2030)
2.2 Chronic Obstructive Pulmonary Diseases Drugs Growth Trends by Region
2.2.1 Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Chronic Obstructive Pulmonary Diseases Drugs Historic Market Size by Region (2019-2024)
2.2.3 Chronic Obstructive Pulmonary Diseases Drugs Forecasted Market Size by Region (2025-2030)
2.3 Chronic Obstructive Pulmonary Diseases Drugs Market Dynamics
2.3.1 Chronic Obstructive Pulmonary Diseases Drugs Industry Trends
2.3.2 Chronic Obstructive Pulmonary Diseases Drugs Market Drivers
2.3.3 Chronic Obstructive Pulmonary Diseases Drugs Market Challenges
2.3.4 Chronic Obstructive Pulmonary Diseases Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Obstructive Pulmonary Diseases Drugs Players by Revenue
3.1.1 Global Top Chronic Obstructive Pulmonary Diseases Drugs Players by Revenue (2019-2024)
3.1.2 Global Chronic Obstructive Pulmonary Diseases Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Chronic Obstructive Pulmonary Diseases Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chronic Obstructive Pulmonary Diseases Drugs Revenue
3.4 Global Chronic Obstructive Pulmonary Diseases Drugs Market Concentration Ratio
3.4.1 Global Chronic Obstructive Pulmonary Diseases Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Obstructive Pulmonary Diseases Drugs Revenue in 2023
3.5 Chronic Obstructive Pulmonary Diseases Drugs Key Players Head office and Area Served
3.6 Key Players Chronic Obstructive Pulmonary Diseases Drugs Product Solution and Service
3.7 Date of Enter into Chronic Obstructive Pulmonary Diseases Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Obstructive Pulmonary Diseases Drugs Breakdown Data by Type
4.1 Global Chronic Obstructive Pulmonary Diseases Drugs Historic Market Size by Type (2019-2024)
4.2 Global Chronic Obstructive Pulmonary Diseases Drugs Forecasted Market Size by Type (2025-2030)
5 Chronic Obstructive Pulmonary Diseases Drugs Breakdown Data by Application
5.1 Global Chronic Obstructive Pulmonary Diseases Drugs Historic Market Size by Application (2019-2024)
5.2 Global Chronic Obstructive Pulmonary Diseases Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Chronic Obstructive Pulmonary Diseases Drugs Market Size (2019-2030)
6.2 North America Chronic Obstructive Pulmonary Diseases Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2019-2024)
6.4 North America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size (2019-2030)
7.2 Europe Chronic Obstructive Pulmonary Diseases Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2019-2024)
7.4 Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size (2019-2030)
8.2 Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size (2019-2030)
9.2 Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2019-2024)
9.4 Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size (2019-2030)
10.2 Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Circassia Pharmaceuticals
11.1.1 Circassia Pharmaceuticals Company Detail
11.1.2 Circassia Pharmaceuticals Business Overview
11.1.3 Circassia Pharmaceuticals Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.1.4 Circassia Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
11.1.5 Circassia Pharmaceuticals Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Detail
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.2.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
11.2.5 AstraZeneca Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Detail
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.3.4 GlaxoSmithKline Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
11.3.5 GlaxoSmithKline Recent Development
11.4 Mylan
11.4.1 Mylan Company Detail
11.4.2 Mylan Business Overview
11.4.3 Mylan Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.4.4 Mylan Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
11.4.5 Mylan Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Detail
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.5.4 Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
11.5.5 Boehringer Ingelheim Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.6.4 Pfizer Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 Almirall
11.7.1 Almirall Company Detail
11.7.2 Almirall Business Overview
11.7.3 Almirall Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.7.4 Almirall Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
11.7.5 Almirall Recent Development
11.8 Abbott Laboratories
11.8.1 Abbott Laboratories Company Detail
11.8.2 Abbott Laboratories Business Overview
11.8.3 Abbott Laboratories Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.8.4 Abbott Laboratories Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
11.8.5 Abbott Laboratories Recent Development
11.9 Novartis
11.9.1 Novartis Company Detail
11.9.2 Novartis Business Overview
11.9.3 Novartis Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.9.4 Novartis Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
11.9.5 Novartis Recent Development
11.10 Teva Pharmaceutical Industries
11.10.1 Teva Pharmaceutical Industries Company Detail
11.10.2 Teva Pharmaceutical Industries Business Overview
11.10.3 Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.10.4 Teva Pharmaceutical Industries Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
11.10.5 Teva Pharmaceutical Industries Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Oral Medicine
Table 3. Key Players of Injection Medicine
Table 4. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Chronic Obstructive Pulmonary Diseases Drugs Market Share by Region (2019-2024)
Table 8. Global Chronic Obstructive Pulmonary Diseases Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Chronic Obstructive Pulmonary Diseases Drugs Market Share by Region (2025-2030)
Table 10. Chronic Obstructive Pulmonary Diseases Drugs Market Trends
Table 11. Chronic Obstructive Pulmonary Diseases Drugs Market Drivers
Table 12. Chronic Obstructive Pulmonary Diseases Drugs Market Challenges
Table 13. Chronic Obstructive Pulmonary Diseases Drugs Market Restraints
Table 14. Global Chronic Obstructive Pulmonary Diseases Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Chronic Obstructive Pulmonary Diseases Drugs Market Share by Players (2019-2024)
Table 16. Global Top Chronic Obstructive Pulmonary Diseases Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Diseases Drugs as of 2023)
Table 17. Ranking of Global Top Chronic Obstructive Pulmonary Diseases Drugs Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Chronic Obstructive Pulmonary Diseases Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Chronic Obstructive Pulmonary Diseases Drugs Product Solution and Service
Table 21. Date of Enter into Chronic Obstructive Pulmonary Diseases Drugs Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Chronic Obstructive Pulmonary Diseases Drugs Revenue Market Share by Type (2019-2024)
Table 25. Global Chronic Obstructive Pulmonary Diseases Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Chronic Obstructive Pulmonary Diseases Drugs Revenue Market Share by Type (2025-2030)
Table 27. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Chronic Obstructive Pulmonary Diseases Drugs Revenue Market Share by Application (2019-2024)
Table 29. Global Chronic Obstructive Pulmonary Diseases Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Chronic Obstructive Pulmonary Diseases Drugs Revenue Market Share by Application (2025-2030)
Table 31. North America Chronic Obstructive Pulmonary Diseases Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 46. Circassia Pharmaceuticals Company Detail
Table 47. Circassia Pharmaceuticals Business Overview
Table 48. Circassia Pharmaceuticals Chronic Obstructive Pulmonary Diseases Drugs Product
Table 49. Circassia Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024) & (US$ Million)
Table 50. Circassia Pharmaceuticals Recent Development
Table 51. AstraZeneca Company Detail
Table 52. AstraZeneca Business Overview
Table 53. AstraZeneca Chronic Obstructive Pulmonary Diseases Drugs Product
Table 54. AstraZeneca Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024) & (US$ Million)
Table 55. AstraZeneca Recent Development
Table 56. GlaxoSmithKline Company Detail
Table 57. GlaxoSmithKline Business Overview
Table 58. GlaxoSmithKline Chronic Obstructive Pulmonary Diseases Drugs Product
Table 59. GlaxoSmithKline Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024) & (US$ Million)
Table 60. GlaxoSmithKline Recent Development
Table 61. Mylan Company Detail
Table 62. Mylan Business Overview
Table 63. Mylan Chronic Obstructive Pulmonary Diseases Drugs Product
Table 64. Mylan Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024) & (US$ Million)
Table 65. Mylan Recent Development
Table 66. Boehringer Ingelheim Company Detail
Table 67. Boehringer Ingelheim Business Overview
Table 68. Boehringer Ingelheim Chronic Obstructive Pulmonary Diseases Drugs Product
Table 69. Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024) & (US$ Million)
Table 70. Boehringer Ingelheim Recent Development
Table 71. Pfizer Company Detail
Table 72. Pfizer Business Overview
Table 73. Pfizer Chronic Obstructive Pulmonary Diseases Drugs Product
Table 74. Pfizer Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024) & (US$ Million)
Table 75. Pfizer Recent Development
Table 76. Almirall Company Detail
Table 77. Almirall Business Overview
Table 78. Almirall Chronic Obstructive Pulmonary Diseases Drugs Product
Table 79. Almirall Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024) & (US$ Million)
Table 80. Almirall Recent Development
Table 81. Abbott Laboratories Company Detail
Table 82. Abbott Laboratories Business Overview
Table 83. Abbott Laboratories Chronic Obstructive Pulmonary Diseases Drugs Product
Table 84. Abbott Laboratories Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024) & (US$ Million)
Table 85. Abbott Laboratories Recent Development
Table 86. Novartis Company Detail
Table 87. Novartis Business Overview
Table 88. Novartis Chronic Obstructive Pulmonary Diseases Drugs Product
Table 89. Novartis Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024) & (US$ Million)
Table 90. Novartis Recent Development
Table 91. Teva Pharmaceutical Industries Company Detail
Table 92. Teva Pharmaceutical Industries Business Overview
Table 93. Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Diseases Drugs Product
Table 94. Teva Pharmaceutical Industries Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024) & (US$ Million)
Table 95. Teva Pharmaceutical Industries Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Chronic Obstructive Pulmonary Diseases Drugs Market Share by Type: 2023 VS 2030
Figure 3. Oral Medicine Features
Figure 4. Injection Medicine Features
Figure 5. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Chronic Obstructive Pulmonary Diseases Drugs Market Share by Application: 2023 VS 2030
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Others Case Studies
Figure 10. Chronic Obstructive Pulmonary Diseases Drugs Report Years Considered
Figure 11. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Chronic Obstructive Pulmonary Diseases Drugs Market Share by Region: 2023 VS 2030
Figure 14. Global Chronic Obstructive Pulmonary Diseases Drugs Market Share by Players in 2023
Figure 15. Global Top Chronic Obstructive Pulmonary Diseases Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Diseases Drugs as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Chronic Obstructive Pulmonary Diseases Drugs Revenue in 2023
Figure 17. North America Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Chronic Obstructive Pulmonary Diseases Drugs Market Share by Country (2019-2030)
Figure 19. United States Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Chronic Obstructive Pulmonary Diseases Drugs Market Share by Country (2019-2030)
Figure 23. Germany Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Share by Region (2019-2030)
Figure 31. China Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Share by Country (2019-2030)
Figure 39. Mexico Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Share by Country (2019-2030)
Figure 43. Turkey Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Circassia Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
Figure 46. AstraZeneca Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
Figure 47. GlaxoSmithKline Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
Figure 48. Mylan Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
Figure 49. Boehringer Ingelheim Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
Figure 50. Pfizer Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
Figure 51. Almirall Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
Figure 52. Abbott Laboratories Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
Figure 53. Novartis Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
Figure 54. Teva Pharmaceutical Industries Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2019-2024)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
